Prediction of CYP2C9-mediated drug-drug interactions: A comparison using data from recombinant enzymes and human hepatocytes

Drug Metabolism and Disposition

Volumn 33, Issue 11, 2005, Pages 1700-1707

  McGinnity, Dermot F ^a   Tucker, James ^a   Trigg, Steve ^a   Riley, Robert J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLIMIDAZOLE; AMIODARONE; BENZBROMARONE; CLOTRIMAZOLE; CYTOCHROME P450 2C9; DICLOFENAC; FLUCONAZOLE; FLUINDOSTATIN; IBUPROFEN; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; MICONAZOLE; NAPROXEN; O DEMETHYLASE; OXYGENASE; PHENYTOIN; PIROXICAM; QUININE; RECOMBINANT ENZYME; SERTRALINE; SULFAMETHIZOLE; SULFAPHENAZOLE; SULFINPYRAZONE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN; ZAFIRLUKAST;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; LIVER CELL; PREDICTION; PRIORITY JOURNAL; SIMULATION;

AMIODARONE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZBROMARONE; DICLOFENAC; DRUG INTERACTIONS; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; KINETICS; NAPROXEN; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

CINCHONA PUBESCENS;

EID: 27544497701     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005884     Document Type: Article

References (42)

1. Ahmad S and Wolfe S (1995) Cisapride and torsades de pointes. Lancet 345:508.
2. Andersson TB, Bredberg E, Ericsson H, and Sjoeberg H (2004) An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 32:715-721.
3. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
4. Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425.
5. Ayrton J, Plumb R, Leavens WJ, Mallett D, Dickins M, and Dear GJ (1998) Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Commun Mass Spectrom 12:217-224.
6. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
7. Blanchard N, Richert L, Coassolo P, and Lave T (2004) Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5:147-156.
8. Boobis AR, McKillop D, Robinson DT, Adams DA, and McCormick DJ (1998) Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 28:493-506.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Cohen LH, Remley MJ, Raunig D, and Vaz ADN (2003) In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015.
11. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, and Yap SH (2000) Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 21:353-364.
12. Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8:457-471.
13. Di Marco A, Yao D, and Laufer R (2003) Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem 270:3768-3777.
14. Gillette J (1963) Drug metabolism by enzyme mechanisms. Prog Drug Res 6:55-57.
15. Gomez-Lechon MJ, Ponsoda X, Bort R, and Castell JV (2001) The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. ATLA 29:225-231.
16. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513-1518.
17. Hutzler JM, Hauer MJ, and Tracy TS (2001) Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 29:1029-1034.
18. Hutzler JM, Messing DM, and Wienkers LC (2005) Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Discov Dev 8:51-58.
19. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
20. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
21. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
22. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
23. Jankel CA and Fitterman LK (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Safety 9:51-59.
24. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
25. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, and Dayer P (1999) Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 55:559-565.
26. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
27. Li AP (1999) Overview: hepatocytes and cryopreservation-a personal historical perspective. Chem -Biol Interact 121:1-5.
28. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability and drug-drug interaction potential. Chem-Biol Interact 121:17-35.
29. Locuson CW, Rock DA, and Jones JP (2004) Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 43:6948-6958.
30. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
31. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
32. Moody GC, Griffin SJ, Mather AN, McGinnity DF, and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53-75.
33. Oleson FB, Berman CL, and Li AP (2004) An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem-Biol Interact 150:137-147.
34. Riley RJ (2001) The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Dev 4:45-54.
35. Riley RJ and Grime K (2004) Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discov Today 1:365-372.
36. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
37. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today 1:441-448.
38. Shou M (2005) Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discov Dev 8:66-77.
39. Umeda S, Harakawa N, Yamamoto M, and Ueno K (2005) Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull 28:212-216.
40. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459.
41. Weaver R, Graham KS, Beattie IG, and Riley RJ (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966.
42. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861.